FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Invention is a method for preparing a vaccine influenza virus antigen, comprising a step of fragmenting a biological membrane associated with said vaccine antigen by bringing said biological membrane into contact with at least one calixarene, where the influenza virus is selected from influenza A and influenza viruses B, further comprising a stage of dialysis vaccine antigen; an influenza virus vaccine comprising an effective amount of the influenza virus vaccine antigen produced by the method, as per any of cl. 1–4, calixarene of formula (II) in form of an excipient in amount of 0.1 to 1000 mcg of the total weight of the vaccine and a pharmaceutically acceptable carrier; use of calixarene of formula.
EFFECT: invention widens the spectrum of agents for producing vaccine antigens.
8 cl, 4 dwg, 8 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
PASSAGE VECTOR AND VACCINE FOR TUBERCULOSIS | 2007 |
|
RU2453603C2 |
IMPROVED VACCINATION AGAINST INFLUENZA | 2013 |
|
RU2599496C2 |
INFLUENZA VACCINE | 2011 |
|
RU2583297C2 |
MUCOSAL INFLUENZA VIRUS VACCINE AND METHOD FOR INFLUENZA PREVENTION | 2004 |
|
RU2390351C2 |
BACULOVIRUS VECTOR AND USE THEREOF | 2007 |
|
RU2588464C2 |
VACCINE AGAINST INFLUENZA AND METHOD FOR ITS PREPARATION | 2013 |
|
RU2523614C1 |
METHOD OF PRODUCING ANTIGEN OR ANTIGENS FOR PRODUCTION OF INFLUENZA VACCINE AND A VACCINE BASED ON IT | 2019 |
|
RU2710239C1 |
METHOD FOR OBTAINING A TETRAVALENT VACCINE FOR THE PREVENTION OF INFLUENZA | 2020 |
|
RU2754398C1 |
VACCINE COMPOSITION | 2013 |
|
RU2655627C2 |
VACCINE COMPOSITION FOR USE IN IMMUNO-COMPROMISED POPULATIONS | 2013 |
|
RU2661408C2 |
Authors
Dates
2019-10-15—Published
2015-08-28—Filed